Identification of 4′-Thiouridine as an Orally Available Antiviral Agent Targeting Both RdRp and NiRAN Functions of SARS-CoV-2 Nsp12
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Minjae Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Thiouridine, COVID-19 Drug Treatment. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Ministry of Health and Welfare, Ministry of Science and ICT, South Korea, National Research Foundation of Korea.
Abstract (Originalsprache)
Through screening of a nucleos(t)ide-focused chemical library, we identified 4'-thiouridine (1) as a potent antiviral agent against SARS-CoV-2 in Vero cells, with an EC50 value of 1.71 μM and a CC50 value exceeding 100 μM. Its triphosphate metabolite, compound 8, inhibited the RNA-dependent RNA polymerase activity of the SARS-CoV-2 Nsp12-Nsp7-Nsp82 complex, terminating nascent RNA synthesis through misincorporation. Additionally, compound 8 suppressed the function of the NiRAN domain of Nsp12, effectively blocking both RNAylation and NMPylation of Nsp9. Pharmacokinetic analysis in mice showed excellent oral bioavailability of compound 1. Oral administration at 100 mg/kg/day, twice daily for 5 days, protected mice from lethal SARS-CoV-2 infection, resulting in 40% survival and near-complete recovery of body weight by day 14 postinfection. Compound 1 also exhibited broad-spectrum activity against various coronaviruses and other RNA viruses. These findings highlight that compound 1 is a promising orally available antiviral candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
- Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.
- Department of Medicinal Chemistry and Pharmacology, University of Science and Technology (UST), Daejeon 34113, Republic of Korea.
- Graduate School of Pharmaceutical Science, Tokushima University, Tokushima 770-8505, Japan.
- Future Medicine Co., Ltd, 54 Changup-ro, Sujeong-gu, Seongnam, Gyeonggi-do 13449, Republic of Korea.
ORCID-Profile: Inseong Jo, Soo Bong Han, Dnyandev B Jarhad, Noriaki Minakawa, Meehyein Kim, Lak Shin Jeong
Förderung
- Ministry of Health and Welfare
- Ministry of Science and ICT, South Korea
- National Research Foundation of Korea
Zitieren
APA
Kim, M., Lee, M. K., Jo, I., Jang, Y., Han, S. B., Lee, J., Yang, A., Jarhad, D. B., Choi, H., Nogi, Y., Saito-Tarashima, N., Minakawa, N., Kim, M., & Jeong, L. S. (2025). Identification of 4′-Thiouridine as an Orally Available Antiviral Agent Targeting Both RdRp and NiRAN Functions of SARS-CoV-2 Nsp12. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02874
Vancouver
Kim M, Lee MK, Jo I, Jang Y, Han SB, Lee J, et al. Identification of 4′-Thiouridine as an Orally Available Antiviral Agent Targeting Both RdRp and NiRAN Functions of SARS-CoV-2 Nsp12. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02874
BibTeX
@article{Kim2025,
author = {Kim, Minjae and Lee, Myoung Kyu and Jo, Inseong and Jang, Yejin and Han, Soo Bong and Lee, Juyeon and Yang, Ayeon and Jarhad, Dnyandev B and Choi, Hongseok and Nogi, Yuhei and Saito-Tarashima, Noriko and Minakawa, Noriaki and Kim, Meehyein and Jeong, Lak Shin},
title = {Identification of 4′-Thiouridine as an Orally Available Antiviral Agent Targeting Both RdRp and NiRAN Functions of SARS-CoV-2 Nsp12},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02874}
}
EUVIMED